Quarterly report pursuant to Section 13 or 15(d)

REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)

v3.24.3
REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)
9 Months Ended
Sep. 30, 2024
REVENUES FROM CONTRACTS WITH CUSTOMERS  
Schedule of disaggregation of net revenues

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three-Month Periods Ended September 30, 

​

Nine-Month Periods Ended September 30, 

($ in thousands)

    

2024

    

2023

    

2024

    

2023

Qbrexza®

​

$

7,583

​

$

5,865

​

$

19,435

​

$

18,038

Accutane®

​

 

3,996

​

 

4,882

​

 

15,534

​

 

15,109

Amzeeq®

​

​

1,542

​

​

2,336

​

​

3,503

​

​

4,904

Zilxi®

​

​

558

​

​

681

​

​

1,200

​

​

1,567

Other / legacy

​

​

950

​

​

1,515

​

​

2,842

​

​

4,787

Total product revenues

​

$

14,629

​

$

15,279

​

$

42,514

​

$

44,405

Schedule of other revenue

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

    

Three-Month Periods Ended September 30,

    

Nine-Month Periods Ended September 30,

($in thousands)

​

2024

    

2023

​

2024

    

2023

Non-refundable upfront payment from Maruho

 

$

—

 

$

19,000

 

$

—

 

$

19,000

Royalties on sales of Rapifort® Wipes 2.5%

​

​

—

​

​

260

​

​

—

​

​

519

Total other revenue

​

$

—

​

$

19,260

​

$

—

​

$

19,519